苯基丁氮酮
医学
优势比
内科学
置信区间
胃肠病学
作者
Nahum Y. Shpigel,M. Winkler,A. Saran,G. Zrv
出处
期刊:Journal of Veterinary Medicine Series A-physiology Pathology Clinical Medicine
[Wiley]
日期:1996-02-12
卷期号:43 (1-10): 331-336
被引量:8
标识
DOI:10.1111/j.1439-0442.1996.tb00460.x
摘要
Summary The efficacy of phenylbutazone vs. dipyrone for the treatment of acute clinical mastitis were compared in a clinical trial. All cows were treated with 20 g sulfadiazine and 4 g trimethoprim i.m. upon diagnosis and half dosage once daily thereafter. In addition, the NSAIDs treated cows received once daily either 4 g phenylbutazone or 20 g dipyrone i.m. for the duration of the antimicrobial therapy. In all treatment groups the major causative organisms were coliforms. Recovery rates for the controls, the phenylbutazone and dipyrone treatment groups were 81.8%, 89.4% and 86.6%, respectively. Recovery was evaluated by the logistic regression analysis, the odds ratios (OR) and their 95% confidence interval (CI) of treatment success for phenylbutazone and dipyrone treatments relative to the control treatment were calculated. Odds ratio of recovery was high for phenylbutazone (OR = 2.42; CI = 0.98‐5.96; P = 0.054) as well as for dipyrone (OR = 1.71; CI = 0.98‐3.00; P = 0.060), demonstrating a strong trend towards improved recovery in NSAID groups. The odds of treatment failure for the phenylbutazone group relative to the dipyrone group was 0.71 with 95% CI of 0.28‐1.78. Clearly no significant difference could be demonstrated between phenylbutazone and dipyrone in this field trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI